ARTICLE | Management Tracks
Pfizer’s Dormitzer to head GSK’s vaccine R&D
Phil Dormitzer is leaving Pfizer, where he has been scientific lead for development of the Comirnaty COVID-19 vaccine
November 30, 2021 11:51 PM UTC
Updated on Oct 14, 2022 at 5:15 PM UTC
GSK has recruited Phil Dormitzer, a veteran vaccine scientist who played a key role in a crash program to head-off an H1N1 influenza pandemic and has been a leader in mRNA-based COVID-19 vaccine development, as global head of vaccines R&D.
Dormitzer will join GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) from Pfizer Inc. (NYSE:PFE), where he is VP and CSO for RNA and viral vaccines. He will report to Hal Barron, GSK’s CSO and president for R&D, and will join GSK’s R&D Leadership and Vaccines Leadership teams...